[
  {
    "ts": null,
    "headline": "AbbVie Stock Falls 4% -- What Investors Need to Know",
    "summary": "It's no reason to stay up at night.",
    "url": "https://finnhub.io/api/news?id=1825f645b526920c37773980bc89bc058fb08ab817a7fda401199dd6bc519d68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763381820,
      "headline": "AbbVie Stock Falls 4% -- What Investors Need to Know",
      "id": 137504090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "It's no reason to stay up at night.",
      "url": "https://finnhub.io/api/news?id=1825f645b526920c37773980bc89bc058fb08ab817a7fda401199dd6bc519d68"
    }
  },
  {
    "ts": null,
    "headline": "LUPRON DEPOT速 new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer",
    "summary": "AbbVie (NYSE: ABBV) announced today that a new 6-month 45mg LUPRON DEPOT速 (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month).1 LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Cana",
    "url": "https://finnhub.io/api/news?id=e9bcfb0e7bfaf758490db3a68186630079c016b58ca78cb6e704aeee7b616352",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763380860,
      "headline": "LUPRON DEPOT速 new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer",
      "id": 137504091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) announced today that a new 6-month 45mg LUPRON DEPOT速 (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month).1 LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Cana",
      "url": "https://finnhub.io/api/news?id=e9bcfb0e7bfaf758490db3a68186630079c016b58ca78cb6e704aeee7b616352"
    }
  }
]